Friday, August 15, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer

July 17, 2024
in Cancer
Reading Time: 4 mins read
0
Oncotarget
66
SHARES
599
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

“[…] results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”

Oncotarget

Credit: 2024 Tolmeijer et al.

ADVERTISEMENT

“[…] results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”

BUFFALO, NY- July 17, 2024 – A new editorial paper was published in Oncotarget’s Volume 15 on July 2, 2024, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.”

In this new editorial, researchers S.H. Tolmeijer, E. Boerrigter, N.P. Van Erp, and Niven Mehra from Radboud University Medical Center discuss metastatic castration resistant prostate cancer (mCRPC). mCRPC is lethal, but the number of life-prolonging systemic treatments available for mCRPC has expanded over the years. Real world data suggest that the most common first-line therapy for mCRPC was treatment with an androgen receptor pathway inhibitor (ARPI), being either enzalutamide or abiraterone, although more patients will nowadays receive ARPI and/or docetaxel already for hormone sensitive prostate cancer (HSPC). 

Recent clinical trial data suggest potential benefit of adding poly-ADP ribose polymerase inhibitors (PARPi) or lutetium-117-prostate-specific membrane antigen (LuPSMA) to first-line mCRPC treatment with ARPIs in a subset of patients. As these different drug classes are associated with different toxicity profiles and significant costs, it is highly important to identify which patients experience durable benefit from monotherapy ARPI and which patients would potentially benefit from treatment intensification or therapy switch.

“Research by Tolmeijer et al. 2023, published in Clinical Cancer Research [13], suggests that the detection of circulating tumor DNA (ctDNA) at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.”

 

Continue reading: DOI: https://doi.org/10.18632/oncotarget.28599 

Correspondence to: Niven Mehra

Email: niven.mehra@radboudumc.nl 

Keywords: ctDNA, prostate cancer, liquid biopsy, biomarker, androgen receptor pathway inhibitors

Click here to sign up for free Altmetric alerts about this article.
 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

  • X, formerly Twitter
  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • Pinterest
  • Reddit
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Oncotarget Journal Office

6666 East Quaker Street., Suite 1

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###



Journal

Oncotarget

DOI

10.18632/oncotarget.28599

Method of Research

Experimental study

Subject of Research

People

Article Title

Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer

Article Publication Date

2-Jul-2024

Share26Tweet17
Previous Post

NYU Tandon School of Engineering welcomes hundreds of city students into its free summer courses

Next Post

Neuroscience 2024 Media Registration Now Open

Related Posts

blank
Cancer

Precision Nanobody Therapy Breaks New Ground in Targeting Lung Cancer Tumors

August 15, 2025
blank
Cancer

One in Three U.S. Adults Unaware of HPV’s Link to Cancer

August 15, 2025
blank
Cancer

Rare Li-Fraumeni Syndrome Case with Dual Malignancies

August 15, 2025
blank
Cancer

BU Researchers Uncover Mutational Signatures and Tumor Dynamics in Chinese Patient Cohort

August 15, 2025
blank
Cancer

Exploring Fetal MRI Insights in Conjoined Twins

August 15, 2025
blank
Cancer

Harnessing Bacteria to Deliver Viruses Directly into Tumors

August 15, 2025
Next Post
Neuroscience 2024 Media Registration Now Open

Neuroscience 2024 Media Registration Now Open

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27533 shares
    Share 11010 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    947 shares
    Share 379 Tweet 237
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Rewrite Illuminating photoreceptors: TGFβ signaling modulates the severeness of retinal degeneration as a headline for a science magazine post, using no more than 8 words
  • Partial Flood Defenses Heighten Risks, Inequality in Cities
  • Expanding Rock Extraction Boosts Enhanced Weathering Efficiency
  • Loop Quantum Gravity: Black Hole Effects Rewritten

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,859 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading